Minoryx Therapeutics

Company snapshot

Minoryx is a registration stage biotech company focusing on the development of novel therapies for orphan CNS diseases with high unmet medical needs. The company’s lead program, leriglitazone (MIN-102), a novel, brain penetrant and selective PPAR gamma agonist, is being developed in X-linked Adrenoleukodystrophy (X-ALD) and other orphan CNS diseases. The company is backed by a syndicate of experie

• 4 active pipeline program(s) linked via ClinicalTrials.gov.
• 4 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Minoryx Therapeutics. Not investment advice.

Recent activity

Latest pipeline, patent, and corporate events for Minoryx Therapeutics.

1. Jun 8, 2026 Clinical update

   MT-3-01 — Phase 3

2. Jun 8, 2026 Clinical update

   MT-2-04 — Phase 2

3. Jun 8, 2026 Clinical update

   MT-2-02 — Phase 2

4. Jun 8, 2026 Clinical update

   MT-1-02 — Phase 1

View all clinical trial activity →

• What is Minoryx Therapeutics?

  Minoryx Therapeutics S.L is a pharma organization headquartered in EU. Primary therapeutic focus areas include Cerebral adrenoleukodystrophy (cALD), Adrenoleukodystrophy, Rett Syndrome, CEREBRAL X-LINKED ADRENOLEUKODYSTROPHY (CALD). NovaPharmaNews links 4 clinical program(s), 0 d

• Is Minoryx Therapeutics publicly traded?

  Minoryx Therapeutics appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does Minoryx Therapeutics develop or market?

  We link 11 drug profile(s) where Minoryx Therapeutics is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/minoryx-therapeutics-s-l#company-drugs.

• What are the latest developments for Minoryx Therapeutics?

  In the last 12 months our linked public records show 4 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Minoryx Therapeutics focus on?

  Minoryx Therapeutics focuses on Cerebral adrenoleukodystrophy (cALD), Adrenoleukodystrophy, Rett Syndrome based on our analysis of their pipeline programs and drug development activities.